Praxis Posts Q3 Loss of $94.2M; Two FDA Decisions Due by Late January 2027
PRAX sits 69% above its 52-week low of $159.735.
Summary
Praxis reported a Q3 2026 net loss of $94.2 million and $1.3 billion in cash lasting into 2028, while two FDA approval decisions (relutrigine December 27, 2026; ulixacaltamide January 29, 2027) and the EMERALD readout approach.
Key Events · Earnings and Guidance · PRAX
-
Q3 Loss Widens to $94.2M
Net loss was $94.2 million for Q3 2026 versus $73.9 million a year earlier, including $14.9 million of stock-based compensation.
-
G&A Nearly Triples on Launch Prep
General and administrative expense rose to $42.7 million from $12.6 million, with $17.2 million of the increase from personnel costs as commercial teams are hired.
-
Two PDUFA Dates Within Three Months
Relutrigine's PDUFA target action date is December 27, 2026 and ulixacaltamide's is January 29, 2027; both NDAs remain under FDA review.
-
$1.3B Cash Funds Runway Into 2028
Cash, equivalents and marketable securities totaled approximately $1.3 billion at September 30, 2026, up $359.9 million from $926.1 million at December 31, 2025, mainly on January 2026 offering proceeds.
Analysis · PRAX · Life Sciences
The quarter itself is a cash-burn story: the net loss widened to $94.2 million from $73.9 million a year ago, driven largely by G&A jumping to $42.7 million from $12.6 million as Praxis staffs up for launch. What matters more is the calendar — relutrigine has a PDUFA date of December 27, 2026 and ulixacaltamide January 29, 2027, so two approval decisions land within roughly three months. With $1.3 billion in cash funding operations into 2028, the company does not need to raise money to reach those decisions, which removes financing risk from the near-term setup. The EMERALD topline readout in Q4 2026 adds a third binary event before year-end.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRAX was trading at $270.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $159.74 to $392.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.